BriaCell Therapeutics Corporation (BCTX) Quote

These guys do multiple offerings on news. They are notorious for this. Be careful. I have shares not shorting it. Just fyi. GL to all.$BCTX 

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™


https://www.biospace.com/press-releases/briacell-confirms-100-resolution-of-lung-metastasis-with-bria-ots

wow! This is pathetic

Most likely. These Biotechs burn ridiculous amounts of cash on FDA studies.

they selling shares on the news? should easily be above 10+

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient
Treatment well-tolerated and patient remains on study with stable disease elsewhere
Sustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer study
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study. The latest data at four months also demonstrates stable disease elsewhere.

Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4 months of therapy1 (axial and coronal views)

https://ml.globenewswire.com/Resource/Download/19a24c7d-e793-4f57-b0df-c1605b7395dc/briacell-figure-1.png

As shown, the lesion in the patient’s right lung is undetectable after two months and confirmed resolved at 4 months. The updated images supersede those previously reported.

The patient, a 78-year-old woman with metastatic breast cancer (hormone receptor positive, HER2 negative), had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study. At enrollment on November 21, 2024, she had extensive metastases including bone, lymph node and lung involvement. Following Bria-OTS intradermal injections every 2 weeks for six weeks (4 total doses), and subsequent dosing every 3 weeks, the lung metastasis completely resolved with stable disease elsewhere. This response is now confirmed and shows the potentially promising activity of the Bria-OTS platform as monotherapy.

“Despite recent advancements with Antibody-drug-conjugates (ADCs) and immune check point inhibitors (CPIs), many patients, including those with HR+ disease, like BriaCell’s first OTS patient, have very few options,” stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, Ca., and Principal Investigator for the Bria-OTS study. “We are thrilled with our initial data with single agent Bria-OTS showing rapid and strong anti-tumor activity in an HR+ patient and look forward to continuing this novel approach in patients with MBC, and other cancers.”

“This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and provides early validation of BriaCell’s personalized immunotherapy approach,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Bria-OTS is a personalized off-the-shelf immunotherapy, currently under investigation in a Phase 1/2a dose escalation study (ClinicalTrials.gov identifier: NCT06471673) in metastatic recurrent breast cancer. Bria-OTS represents a personalized, next generation, advancement of BriaCell’s lead candidate Bria-IMT™ which is currently in a pivotal Phase 3 study for metastatic breast cancer. The Phase 1/2a clinical trial in metastatic breast cancer is a dose escalation study initially evaluating the safety and efficacy of Bria-OTS as monotherapy and will be followed by Bria-OTS in combination with an immune checkpoint inhibitor.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements,

BCTX..................................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

Trader Alert: Potential Breakout Candidate Issues Big Cancer News! $BCTX is speeding up enrollment in its Phase 3 trial for metastatic breast cancer.

75+ patients enrolled across 54 sites.

Top-line data could come as early as H1 2026.

More details here: https://finance.yahoo.com/news/briacell-enrollment-pace-accelerating-phase-113000724.html

$BCTX In the spotlight the week of 28April
https://www.abstractsonline.com/pp8/#!/20273/presentation/8077

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily pre-treated patients
Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY®
No Bria-IMT related discontinuations reported to date https://www.otcmarkets.com/stock/BCTX/news/story?e&id=3211304

BCTX.............................................................p/m

BCTX: Roger that, Capt.!!

$3.83 + 10% Super low float power 3.33 52 week low ...on watch add a few for now 

priced a best-efforts public offering of 762,500 common shares at $4.00 per share, with expected gross proceeds of $3.05 million before fees and expenses.

Hahahaha 🤣😂

BCTX: I.e., where their 'Investigational Drug Group' consisted of 400-PATIENTS --- vs. merely just ONE, as in their bogus PR today!!!

BCTX: Could you imagine where the PRICE of this stock would be right now, if this Firm had PR'd legitimate STATISTICS to the effect that 75% of the 'Investigational Drug Group' enjoyed 100% remission of their metastasized LUNG CANCERS --- when compared to the 'Placebo Group", & all other 'Control Groups' & 'Standard of Care Groups'??? (And moreover, this HOAX Company did NOT even entertain ANY 'Control Groups', nor 'Standard of Care Groups', AT ALL!!! Their only experimental 'competition', as it were, was a useless 'PLACEBO GROUP'!!! I myself KNOW this stuff, Peeps!!! Anyone who got suckered by the conspicuous NONSENSE within BCTX's PR today, is patently-STUPID --- even when compared to all universal, 'Standards of Stupidity!!!)


"Tell-it-like-it-is, Oh Great Invest-in-America, Dude!!! You're doing GOD's work, Homeboy!!!"
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

BCTX: At least I can recognized a HOAX, when I see one!! (And they even PR'd a cute 'X-RAY' too, of a TINY SPOT of purported metastasized CANCER that had suddenly disappeared behind their disruptive new ELIXIR!!!)

THE BIO BEAST OF THE DAY...DILUTION WILL KICK IN NOW

One patient all it takes $6.75 .. .."That's one small step for man, one giant leap for mankind." However, Armstrong insisted that he actually said, "That's one small step for a man," though the "a" was not clearly heard in the transmission...

BCTX: Straight-up HOAX!!! (Such a PR is never, never, never DONE behind one patient!!!)

BCTX........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

does seem questionable -- certainly a very impressive result -- but one person only --- abberations do occur

BCTX: Their purported NEWS is a "Statistical Artifact" --- significant of NOTHING!!! No legitimate Pharma firm would ever PR such (One Patient) crap!!!

I'm seeing 2.7m float

BCTX: Something very CREEPY here, Peeps!!! (Be careful!!)

huge news-Treatment with Bria-OTS™ monotherapy resulted in 100% resolution of tumor in the lung of the MBC patient following 4 injection cycles


This 78-year-old woman with metastatic breast cancer (hormone receptor positive, HER2 negative) had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS™ study. At enrollment on Nov 21, 2024, she had extensive metastases including multiple bone, lymph node and lung metastases. Following 4 injections with Bria-OTS™ every 2 weeks, the lung metastasis completely resolved, and she had stable disease elsewhere.

https://feeds.issuerdirect.com/news-release.html?newsid=7417246418288908

BCTX: One patient cured. (Warrants here??)

BCTX $5.90 + 16% 20m floater but news is decent..

BCTX POST SPLIT RUN UNDERWAY

BCTX, new 52 week low

BCTX: It's actually GREEN now in price!!! (Heck, maybe there IS a "God" --- of WOMEN, hopefully!!!! And NOT some clown nailed to a cross in Naples, Italy, 2K years ago!!!!)

BCTX: I sincerely HOPE that this BCTX stock --- with GREAT news for Women's BREAST Cancer concerns --- gets monster short-SQUEEZED, like below!!! Metaphorically speaking, that is.)

Slow and Steady up

BCTX: The Markets simply do NOT give-a-fluck about WOMEN's issues of any sort!!! (BCTX could have PR'd that they have outright CURED all Breast Cancers, but this stock STILL would not have soared in price!!!)

BCTX: The only worrisome thing about anything (Medical) WOMEN's STUFF, is that they rarely if ever SOAR in price. (While mere FLUFF news about anything MEN's Medical issues --- like today's @CADL baloney PR -- often SOAR in price gloriously.)

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the study
Median OS of 13.7 months in breast cancer patients with central nervous system (CNS) metastasis treated with the Bria-IMT™ regimen alone or in combination with an immune check point inhibitor (CPI)
Five BriaCell posters (four today and one on Dec 13 th ) showcase robust survival and clinical benefit data, plus key biomarker data from Phase 2 trial of Bria-IMT™ in metastatic breast cancer (MBC)
Biomarkers identify patients who benefit from treatments with the Bria-IMT™ regimen
No toxicity related discontinuations



https://feeds.issuerdirect.com/news-release.html?newsid=7743652450762128

BCTX: Much more IMPRESSIVE stats. for this BCTX news --- vs. the baloney stats. for @CADL's Prostate Cancer results, which were in truth mere STATISTICAL ARTIFACTS and, as such, significant of NOTHING!!

BCTX OUT ON NEWS

BCTX MASSIVE NEWS FOR THIS CANADIAN BIO

BCTX BLOWING UP

BCTX PUSHING TO TOP OF THE DAILY CLOUD VERY NICE

BCTX..............................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BCTX NICE CANADIAN BIO READY FOR A DOLLAR

BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

HUGE$ In BriaCell's Phase 2 clinical study, patients treated with the same Bria-IMT™ regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients (see Table 1). Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well, including:

Patient 01-009: Overall survival (OS) of 25 months has been reported in a patient who had failed 6 prior treatments prior to the BriaCell regimen. Stable disease and lymph node shrinkage has been recorded during 13 cycles of therapy.
Patient 07-001: OS of 24 months. She had stable disease and received 8 cycles of BriaCell's therapy.
Patient 16-003: OS of 15 months and received 8 cycles of therapy with stable disease. Prior to the BriaCell regimen, she had 7 lines of therapy, which included the progression of disease while on the antibody-drug conjugate (ADC) Enhertu.
Patient 11-018: OS of 14 months. This previously-reported responder with 100% resolution of her brain metastasis has recently completed her 19th cycle of therapy.

$BCTX No serious adverse events related to Bria-IMT™, 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™, Pivotal Phase 3 study patient enrollment completion is expected in mid-2025

BIG NEWS https://feeds.issuerdirect.com/news-release.html?newsid=7546332967366263

BCTX...........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor